(Q36761916)

English

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

scientific article published on 10 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

0 references

author name string

Jeremy Sokolove

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Michael Schiff

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Roy Fleischmann

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Michael E Weinblatt

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sean E Connolly

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Alyssa Johnsen

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jin Zhu

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Michael A Maldonado

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Salil Patel

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

William H Robinson

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

10 September 2015

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

75

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

709-714

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

The influence of ACPA status and characteristics on the course of RA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Use and significance of anti-CCP autoantibodies in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

29 September 2017

A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819608

5 September 2018

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207942

21 January 2018

Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207942

21 January 2018

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26359449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2015-207942

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36761916&oldid=1516015766"